- Home
- CRVO vs TLSA Comparison
CRVO vs TLSA Comparison
Compare CRVO & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVO
- TLSA
- Stock Information
- Founded
- CRVO 2001
- TLSA 2013
- Country
- CRVO United States
- TLSA United Kingdom
- Employees
- CRVO N/A
- TLSA N/A
- Industry
- CRVO Biotechnology: Pharmaceutical Preparations
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- CRVO Health Care
- TLSA Health Care
- Exchange
- CRVO Nasdaq
- TLSA Nasdaq
- Market Cap
- CRVO 95.4M
- TLSA 87.8M
- IPO Year
- CRVO N/A
- TLSA 2000
- Fundamental
- Price
- CRVO $9.80
- TLSA $1.07
- Analyst Decision
- CRVO Strong Buy
- TLSA
- Analyst Count
- CRVO 8
- TLSA 0
- Target Price
- CRVO $25.43
- TLSA N/A
- AVG Volume (30 Days)
- CRVO 1.5M
- TLSA 363.4K
- Earning Date
- CRVO 05-13-2025
- TLSA 05-09-2025
- Dividend Yield
- CRVO N/A
- TLSA N/A
- EPS Growth
- CRVO N/A
- TLSA N/A
- EPS
- CRVO N/A
- TLSA N/A
- Revenue
- CRVO $9,737,974.00
- TLSA N/A
- Revenue This Year
- CRVO N/A
- TLSA N/A
- Revenue Next Year
- CRVO N/A
- TLSA N/A
- P/E Ratio
- CRVO N/A
- TLSA N/A
- Revenue Growth
- CRVO 36.29
- TLSA N/A
- 52 Week Low
- CRVO $1.80
- TLSA $0.49
- 52 Week High
- CRVO $25.69
- TLSA $1.91
- Technical
- Relative Strength Index (RSI)
- CRVO 55.40
- TLSA 53.21
- Support Level
- CRVO $9.03
- TLSA $0.76
- Resistance Level
- CRVO $10.89
- TLSA $1.13
- Average True Range (ATR)
- CRVO 1.90
- TLSA 0.11
- MACD
- CRVO -0.29
- TLSA -0.00
- Stochastic Oscillator
- CRVO 32.37
- TLSA 85.00
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.